OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Bictegravir/emtricitabine/tenofovir alafenamide as initial treatment for HIV-1: five-year follow-up from two randomized trials
Paul E. Sax, José Ramón Arribas, Chloe Orkin, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101991-101991
Open Access | Times Cited: 41
Paul E. Sax, José Ramón Arribas, Chloe Orkin, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101991-101991
Open Access | Times Cited: 41
Showing 1-25 of 41 citing articles:
Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in treatment-naïve and treatment-experienced people with HIV: 12-month virologic effectiveness and safety outcomes in the BICSTaR Japan cohort
Yoshiyuki Yokomaku, Katsuji Teruya, Dai Watanabe, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0313338-e0313338
Open Access | Times Cited: 1
Yoshiyuki Yokomaku, Katsuji Teruya, Dai Watanabe, et al.
PLoS ONE (2025) Vol. 20, Iss. 1, pp. e0313338-e0313338
Open Access | Times Cited: 1
Effects of Antiretroviral Treatment on Central and Peripheral Immune Response in Mice with EcoHIV Infection
Qiaowei Xie, Mark D. Namba, Lauren A. Buck, et al.
Cells (2024) Vol. 13, Iss. 10, pp. 882-882
Open Access | Times Cited: 4
Qiaowei Xie, Mark D. Namba, Lauren A. Buck, et al.
Cells (2024) Vol. 13, Iss. 10, pp. 882-882
Open Access | Times Cited: 4
Safety and efficacy of lamivudine/dolutegravir vs. bictegravir/emtricitabine/tenofovir alafenamide in antiretroviral-naive adults with HIV-1 infection in Shanghai, China: a single-centre retrospective study
Junyang Yang, Lin Wang, Xiaoran Zhang, et al.
Journal of Medical Microbiology (2025) Vol. 74, Iss. 1
Closed Access
Junyang Yang, Lin Wang, Xiaoran Zhang, et al.
Journal of Medical Microbiology (2025) Vol. 74, Iss. 1
Closed Access
Pharmacokinetics, safety and efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide in children with HIV aged from 2 years and weighing at least 14 kg
Eva Natukunda, Aditya H. Gaur, Pope Kosalaraksa, et al.
Journal of the International AIDS Society (2025) Vol. 28, Iss. 2
Open Access
Eva Natukunda, Aditya H. Gaur, Pope Kosalaraksa, et al.
Journal of the International AIDS Society (2025) Vol. 28, Iss. 2
Open Access
Bictegravir/emtricitabine/tenofovir alafenamide in clinical practice for people with HIV: final 24-month effectiveness and safety outcomes in key populations in the observational BICSTaR cohort
Benoît Trottier, Chia‐Jui Yang, Dai Watanabe, et al.
HIV Research & Clinical Practice (2025) Vol. 26, Iss. 1
Open Access
Benoît Trottier, Chia‐Jui Yang, Dai Watanabe, et al.
HIV Research & Clinical Practice (2025) Vol. 26, Iss. 1
Open Access
Long-Term Evolution of Renal Function Among People with HIV who Received Tenofovir Alafenamide-Containing Antiretroviral Therapy
Guan‐Jhou Chen, Wen-Chi Huang, Kuan‐Yin Lin, et al.
Infectious Diseases and Therapy (2025)
Open Access
Guan‐Jhou Chen, Wen-Chi Huang, Kuan‐Yin Lin, et al.
Infectious Diseases and Therapy (2025)
Open Access
Three Year Efectiveness of Bictegravir/Emtricitabine/Tenofovir Alafenamide as Switch Strategy in the Real-World
Alejandro de Gea Grela, Rafael Micán, Rosa de Miguel Buckley, et al.
Open Forum Infectious Diseases (2025) Vol. 12, Iss. 3
Open Access
Alejandro de Gea Grela, Rafael Micán, Rosa de Miguel Buckley, et al.
Open Forum Infectious Diseases (2025) Vol. 12, Iss. 3
Open Access
Effectiveness of dolutegravir-based vs boosted darunavir-based first-line 3-drug regimens in people with HIV with advanced disease: a trial emulation
Roberta Gagliardini, Andrea Giacomelli, Cristina Mussini, et al.
International Journal of Infectious Diseases (2025), pp. 107883-107883
Open Access
Roberta Gagliardini, Andrea Giacomelli, Cristina Mussini, et al.
International Journal of Infectious Diseases (2025), pp. 107883-107883
Open Access
Efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide in Black and Hispanic/Latine adults with HIV ‐1 initiating first‐line therapy: 5‐year follow‐up from two phase III studies
Claudia Martorell, Moti Ramgopal, D Hagins, et al.
HIV Medicine (2025)
Open Access
Claudia Martorell, Moti Ramgopal, D Hagins, et al.
HIV Medicine (2025)
Open Access
Long-term metabolic changes with bictegravir/emtricitabine/tenofovir alafenamide or dolutegravir-containing regimens for HIV
Eric S. Daar, Chloe Orkin, Paul E. Sax, et al.
AIDS Research and Therapy (2025) Vol. 22, Iss. 1
Open Access
Eric S. Daar, Chloe Orkin, Paul E. Sax, et al.
AIDS Research and Therapy (2025) Vol. 22, Iss. 1
Open Access
Impact of social determinants of health on time to antiretroviral therapy initiation and HIV viral undetectability for migrants enrolled in a multidisciplinary HIV clinic with rapid, free, and onsite B/F/TAF: ‘The ASAP study’
Anish Arora, Serge Vicente, Kim Engler, et al.
HIV Medicine (2024) Vol. 25, Iss. 5, pp. 600-607
Open Access | Times Cited: 4
Anish Arora, Serge Vicente, Kim Engler, et al.
HIV Medicine (2024) Vol. 25, Iss. 5, pp. 600-607
Open Access | Times Cited: 4
Emergent resistance-associated mutations at first- or second-line HIV-1 virologic failure with second-generation InSTIs in two- and three-drug regimens: the Virostar-1 study
Anne‐Geneviève Marcelin, Cathia Soulié, Marc Wirden, et al.
Journal of Antimicrobial Chemotherapy (2024)
Open Access | Times Cited: 4
Anne‐Geneviève Marcelin, Cathia Soulié, Marc Wirden, et al.
Journal of Antimicrobial Chemotherapy (2024)
Open Access | Times Cited: 4
Real-life data of immune recovery using bictegravir/emtricitabine/tenofovir alafenamide in virologically suppressed people living with HIV. Results at 48–96 weeks of RETROBIC Study
Jesús Troya, Guillermo Pousada, Rafael Micán, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 3, pp. 595-607
Closed Access | Times Cited: 3
Jesús Troya, Guillermo Pousada, Rafael Micán, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 3, pp. 595-607
Closed Access | Times Cited: 3
Switch to bictegravir/emtricitabine/tenofovir alafenamide from dolutegravir-based therapy
Chloe Orkin, Andrea Antinori, Jürgen K. Rockstroh, et al.
AIDS (2024) Vol. 38, Iss. 7, pp. 983-991
Open Access | Times Cited: 3
Chloe Orkin, Andrea Antinori, Jürgen K. Rockstroh, et al.
AIDS (2024) Vol. 38, Iss. 7, pp. 983-991
Open Access | Times Cited: 3
Improvement in insulin sensitivity after switching from an integrase inhibitor‐based regimen to doravirine/tenofovir disoproxil fumarate/lamivudine in people with significant weight gain
Leonardo Calza, Maddalena Giglia, Vincenzo Colangeli, et al.
HIV Medicine (2024) Vol. 25, Iss. 8, pp. 919-926
Closed Access | Times Cited: 3
Leonardo Calza, Maddalena Giglia, Vincenzo Colangeli, et al.
HIV Medicine (2024) Vol. 25, Iss. 8, pp. 919-926
Closed Access | Times Cited: 3
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort
Antonella d’Arminio Monforte, Alessandro Tavelli, Antonio Di Biagio, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 6, pp. 1279-1288
Closed Access | Times Cited: 3
Antonella d’Arminio Monforte, Alessandro Tavelli, Antonio Di Biagio, et al.
Journal of Antimicrobial Chemotherapy (2024) Vol. 79, Iss. 6, pp. 1279-1288
Closed Access | Times Cited: 3
High efficacy of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in Black adults in the United States, including those with pre‐existing HIV resistance and suboptimal adherence
Kristen Andreatta, Michelle L. D’Antoni, Silvia Chang, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 10
Open Access | Times Cited: 3
Kristen Andreatta, Michelle L. D’Antoni, Silvia Chang, et al.
Journal of Medical Virology (2024) Vol. 96, Iss. 10
Open Access | Times Cited: 3
Incidence of low-level viremia and its impact on virologic failure among people living with HIV who started an integrase strand transfer inhibitors: a longitudinal cohort study
Xiaojie Lao, Hanxi Zhang, Meiju Deng, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
Xiaojie Lao, Hanxi Zhang, Meiju Deng, et al.
BMC Infectious Diseases (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 2
New Therapies and Strategies to Curb HIV Infections with a Focus on Macrophages and Reservoirs
Maria Marra, Alessia Catalano, Maria Stefania Sinicropi, et al.
Viruses (2024) Vol. 16, Iss. 9, pp. 1484-1484
Open Access | Times Cited: 2
Maria Marra, Alessia Catalano, Maria Stefania Sinicropi, et al.
Viruses (2024) Vol. 16, Iss. 9, pp. 1484-1484
Open Access | Times Cited: 2
Effectiveness and Safety of BIC/FTC/TAF in Late-Presenting People with HIV-1 Infection
Xiaoyan Yang, Xiaoxin Xie, Yanhua Fu, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 11
Open Access | Times Cited: 2
Xiaoyan Yang, Xiaoxin Xie, Yanhua Fu, et al.
Open Forum Infectious Diseases (2024) Vol. 11, Iss. 11
Open Access | Times Cited: 2
Efficacy and safety profiles of dolutegravir plus lamivudine vs. bictegravir/emtricitabine/tenofovir alafenamide in therapy-naïve adults with HIV-1
Wei Yinghua, Jin Li, Ruhong Xu, et al.
Chinese Medical Journal (2023) Vol. 136, Iss. 22, pp. 2677-2685
Open Access | Times Cited: 6
Wei Yinghua, Jin Li, Ruhong Xu, et al.
Chinese Medical Journal (2023) Vol. 136, Iss. 22, pp. 2677-2685
Open Access | Times Cited: 6
Relationship between adherence to bictegravir/emtricitabine/tenofovir alafenamide fumarate and clinical outcomes in people with HIV in Japan: a claims database analysis
Nao Taguchi, Yi Piao, Annalisa Rubino, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Nao Taguchi, Yi Piao, Annalisa Rubino, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Metabolic Complications Associated with Use of Integrase Strand Transfer Inhibitors (InSTI) for the Treatment of HIV-1 Infection: Focus on Weight Changes, Lipids, Glucose and Bone Metabolism
Stefano Savinelli, Ellen Newman, Patrick Mallon
Current HIV/AIDS Reports (2024) Vol. 21, Iss. 6, pp. 293-308
Open Access | Times Cited: 1
Stefano Savinelli, Ellen Newman, Patrick Mallon
Current HIV/AIDS Reports (2024) Vol. 21, Iss. 6, pp. 293-308
Open Access | Times Cited: 1
B/F/TAF forgiveness to non-adherence
Franco Maggiolo, Lucia Taramasso, Daniela Valenti, et al.
Sexually Transmitted Infections (2024) Vol. 100, Iss. 7, pp. 418-422
Closed Access | Times Cited: 1
Franco Maggiolo, Lucia Taramasso, Daniela Valenti, et al.
Sexually Transmitted Infections (2024) Vol. 100, Iss. 7, pp. 418-422
Closed Access | Times Cited: 1
Twelve-month effectiveness and safety of bictegravir/emtricitabine/tenofovir alafenamide in treatment-naïve and treatment-experienced people with HIV: Findings from the Asia cohort of the BICSTaR study
Y Tseng, Chia‐Jui Yang, Kim Ys, et al.
Journal of Microbiology Immunology and Infection (2024) Vol. 57, Iss. 5, pp. 760-770
Open Access | Times Cited: 1
Y Tseng, Chia‐Jui Yang, Kim Ys, et al.
Journal of Microbiology Immunology and Infection (2024) Vol. 57, Iss. 5, pp. 760-770
Open Access | Times Cited: 1
